Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,847 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07328503RecruitingPhase 2
CD22 CAR T-cells to prevent relapse after CD19 CAR T-cell therapy
This trial tests if giving a second type of CAR T-cell therapy that targets CD22 can help keep B-cell acute lymphoblastic leukemia (ALL) in remission for people who are already in remission after CD19 CAR T-cell treatment. It aims to reduce the risk of the cancer coming back.
Bethesda, MarylandAges 3–65 - NCT07326566RecruitingPhase 2
Silevertinib and chemo for a type of glioblastoma
This trial tests a new drug, silevertinib, combined with temozolomide (a chemotherapy) for people with a newly diagnosed glioblastoma that has certain genetic markers. It aims to see if this combination works better than standard treatment for tumors with these specific features.
Birmingham, AlabamaAges 18 years+ - NCT07325539RecruitingPhase 2
Radiation and immunotherapy with chemo for nose and throat cancer
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
Guangzhou, GuangdongAges 18–65 - NCT07328971RecruitingPhase 3
Vancomycin taper to prevent C. diff from coming back
This trial tests whether a gradual decrease (taper) of vancomycin can stop C. diff infections from returning. It’s for adults with their first or second C. diff infection who can take pills by mouth.
Edmonton, AlbertaAges 18 years+ - NCT05769660RecruitingPhase 1
Study BEY1107 plus temozolomide for recurrent glioblastoma
This Phase 1 study tests the safety and early effectiveness of BEY1107 combined with temozolomide in adults whose glioblastoma has come back or kept growing after standard treatment. If you qualify, you may be able to receive this combination while the researchers closely monitor side effects and tumor response.
SeoulAges 19 years+ - NCT06742892RecruitingPhase 2
Study of HLX43 for advanced liver cancer after standard treatment fails
This trial tests a new drug, HLX43, for people with advanced liver cancer (HCC) that has worsened or caused intolerable side effects after standard treatments like immunotherapy or targeted therapy. The goal is to see if HLX43 can help when other options have stopped working.
Hunan, HunanAges 18–75 - NCT07316361Enrolling by invitationEarly Phase 1
Personalized vaccine for high-risk endometrial cancer
This trial tests a personalized vaccine made from your tumor's unique proteins to help your immune system fight high-risk or advanced endometrial cancer. It is given along with your regular cancer treatments.
Thessaloniki, ThessalonikiAges Any age - NCT06869603Recruiting
Mediterranean diet for recurrent kidney stones and bone health
This trial looks at whether following the Mediterranean diet helps people who get kidney stones over and over again. It also checks how diet affects bone health. If you have had multiple kidney stones, you may be able to join.
NaplesAges 18 years+ - NCT07318831RecruitingPhase 2
Combination drug therapy for relapsed neuroblastoma
This trial tests a combination of four drugs (chidamide, dinutuximab beta, irinotecan, and temozolomide) for children whose neuroblastoma has returned or isn't responding to standard treatment. It aims to see if this mix can shrink the tumor or stop it from growing.
Tianjin, Tianjin MunicipalityAges birth–18 years - NCT07316010RecruitingPhase 2
Liso-cel for lymphoma with minimal residual disease after first treatment
This trial tests a type of CAR T-cell therapy (called liso-cel) for people with large B-cell lymphoma who still have tiny traces of cancer after their first treatment. The goal is to see if liso-cel can get rid of those remaining cancer cells and prevent the cancer from coming back.
Houston, TexasAges 18 years+ - NCT07322783RecruitingPhase 2
Osimertinib plus savolitinib for resistant lung cancer
This trial tests a combination of two targeted drugs (osimertinib and savolitinib) for people with a specific type of advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help patients whose cancer has a low number of MET gene copies.
QingdaoAges 18–80 - NCT07319429RecruitingPhase 2/Phase 3
Fertility-sparing treatment for endometrial cancer based on molecular type
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
Shanghai, Shanghai MunicipalityAges 18–45 - NCT05489289RecruitingPhase 3
AK104 to prevent HCC coming back after surgery
This trial tests whether AK104, taken after liver cancer surgery, can lower the chance that the cancer returns. It is for people with high risk of recurrence but no remaining cancer after surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06095154RecruitingPhase 3
Simplifying radiation planning for nasopharyngeal cancer
This study tests a simpler way to plan radiation for a type of throat cancer called nasopharyngeal carcinoma. It uses a standard method to outline the area needing treatment, which may make planning faster and more consistent.
Fuzhou, FujianAges 18–70 - NCT07307456RecruitingPhase 2
Toripalimab and BCG for high-risk bladder cancer
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07311941Recruiting
Rapid cholesterol lowering for heart disease patients
This study tests whether quickly increasing cholesterol-lowering medication can reduce the risk of another heart attack or stroke. It is for people who have heart disease from blocked arteries.
Shatin, New TerrritoriesAges 18 years+ - NCT06521866RecruitingPhase 2
Study of serplulimab plus standard therapy for advanced colorectal cancer
This trial tests an immunotherapy drug (serplulimab) combined with targeted therapy, chemo, and radiation as a first treatment for people with advanced colorectal cancer that has spread and cannot be surgically removed. It aims to see if this combination can help control the cancer.
Fuzhou, FujianAges 18 years+ - NCT07298473Recruiting
Redo ablation for recurrent atrial fibrillation with Sphere-9 catheter
This trial tests a new catheter and system for people who have had one previous ablation for atrial fibrillation but still have symptoms. It aims to see if a repeat procedure can safely and effectively treat recurrent episodes.
Birmingham, AlabamaAges 18 years+ - NCT06516341Recruiting
Predicting bowel recurrence after surgery for chronic inflammation
This study follows patients with Crohn's disease or ulcerative colitis to see how their intestine heals after surgery. It looks for signs that can predict whether inflammation will return or complications will happen.
Milan, ItalyAges 18–69 - NCT07300449RecruitingPhase 2
Predicting chemo response in children with hepatoblastoma
This trial tests a new way to see if chemotherapy will work for children with hepatoblastoma, a type of liver cancer. It uses a blood test (ctDNA 5hmc) to help predict treatment success and monitor if the cancer comes back.
Guangzhou, GuangdongAges Up to 18 years - NCT07306299RecruitingPhase 1
MRNA vaccine for recurrent high-grade glioma
This trial tests a new mRNA vaccine for people with a type of brain tumor called high-grade glioma that has come back or progressed. The vaccine is designed to help your immune system recognize and attack the tumor cells.
Hangzhou, ZhejiangAges 16 years+ - NCT07298083Recruiting
Identifying markers for MPNST to improve diagnosis and surgery
This trial collects tissue samples from people with MPNST or neurofibroma during surgery to find metabolic markers that could help diagnose MPNST faster and ensure complete removal of tumors.
Houston, TexasAges 1 year+ - NCT07289997RecruitingPhase 2
Combination therapy for advanced AFP-producing gastric cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (apatinib) and a chemotherapy drug (irinotecan hydrochloride) for people with a rare type of advanced stomach cancer called AFP-producing gastric cancer. It is for patients whose cancer did not respond to previous immunotherapy combined with chemotherapy.
Shijiazhuang, HebeiAges 18 years+ - NCT07295262RecruitingEarly Phase 1
New imaging to guide liver cancer surgery
This trial tests a new imaging technique that uses a special dye combined with a chemotherapy drug to help surgeons see and remove liver cancer more precisely during surgery. It is for people with a first-time, single liver tumor that is small and can be surgically removed.
Chengdu, SichuanAges 18–75
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,847 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.